World Journal of Surgery

, Volume 39, Issue 2, pp 424–432 | Cite as

Esophageal Cancer Management: Preoperative CA19.9 and CEA Serum Levels May Identify Occult Advanced Adenocarcinoma

  • Marco ScarpaEmail author
  • Giulia Noaro
  • Luca Saadeh
  • Francesco Cavallin
  • Matteo Cagol
  • Rita Alfieri
  • Mario Plebani
  • Carlo Castoro
Original Scientific Report



Esophagectomy is contraindicated in case of advanced cancer (i.e., carcinomatosis, distant metastasis, and invasion of other organs). In some cases, preoperative imaging may fail to identify advanced neoplasm and esophagectomy is inappropriately planned. The aim of the study was to identify preoperative biomarkers of occult advanced disease that force surgeons to abort the planned esophagectomy.


From 2008 to 2014, 244 consecutive patients were taken to the operative room to have esophagectomy for cancer in our department. All of them had blood test at admission and their preoperative biomarker data were retrieved. Their medical history was collected and the intraoperative findings and outcome were recorded. Non parametric tests, multiple regression analysis, and ROC curves analysis were performed.


In our study group, 14 (5.7 %) patients, scheduled for esophagectomy, were discovered to have occult advanced disease at laparotomy/laparoscopy or at thoracotomy. Six of them had peritoneal carcinomatosis, three had advanced tumor invading other organs, three had small liver metastasis, and two pleural carcinomatosis. In all these cases, esophagectomy was aborted and a feeding jejunostomy was placed. In patients with unresectable esophageal cancer, CA19.9 and CEA serum levels were significantly higher than patients who could have esophagectomy (p < 0.001 and p = 0.003, respectively). CA19.9 and CEA resulted to be accurate biomarkers of occult advanced disease (AUC = 85 %, p < 0.001 and AUC = 73 %, p = 0.002, respectively).


Preoperative CEA and CA19.9 serum levels should be taken in consideration when evaluating patients candidate to esophagectomy for esophageal cancer to prevent inappropriate laparotomy or thoracotomy. If any doubt arises minimally invasive exploration is warranted.


Pancreatic Cancer Esophageal Cancer Esophageal Squamous Cell Carcinoma Peritoneal Carcinomatosis Esophageal Adenocarcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Donahue JM, Nichols FC, Li Z et al (2009) Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 87(2):392–398PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    van Hagen P, Hulshof MC, van Lanschot JJ, Cross Group et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084PubMedCrossRefGoogle Scholar
  3. 3.
    Lin CC, Hsu CH, Cheng JC et al (2007) Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 18:93–98PubMedCrossRefGoogle Scholar
  4. 4.
    Wouters MW, Gooiker GA, van Sandick JW et al (2012) The volume-outcome relation in the surgical treatment of esophageal cancer: a systematic review and meta-analysis. Cancer 118(7):1754–1763PubMedCrossRefGoogle Scholar
  5. 5.
    Bailey SH, Bull DA, Harpole DH et al (2003) Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg 75(1):217–222PubMedCrossRefGoogle Scholar
  6. 6.
    Blackstock AW, Farmer MR, Lovato J et al (2006) A prospective evaluation of the impact of 18-F-fluorodeoxy-d-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 64:455–460PubMedCrossRefGoogle Scholar
  7. 7.
    Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW (2010) Outcomes of patients with esophageal cancer staged with [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 28(31):4714–4721. doi: 10.1200/JCO.2010.30.7702 PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Thomas SN, Zhu F, Schnaar RL, Alves CS, Konstantopoulos K (2008) Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. J Biol Chem 283(23):15647–15655. doi: 10.1074/jbc.M800543200 PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA (1998) The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 35(Pt 1):99–103PubMedCrossRefGoogle Scholar
  10. 10.
    Duffy MJ, Van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O (2003) Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 39(6):718–727. doi: 10.1016/S0959-8049(02)00811-0 PubMedCrossRefGoogle Scholar
  11. 11.
    Perkins G, Slater E, Sanders G, Prichard J (2003) Serum tumor markers. Am Fam Physician 68(6):1075–1082PubMedGoogle Scholar
  12. 12.
    Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33(3):266–270. doi: 10.1016/j.ejso.2006.10.004 PubMedCrossRefGoogle Scholar
  13. 13.
    Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J, Somerfield M, Hayes D, Bast R (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33):5313–5327. doi: 10.1200/JCO.2006.08.2644 PubMedCrossRefGoogle Scholar
  14. 14.
    Sobin L, Wittekind C, UICC (2002) TNM classification of malignant tumors, 6th edn. Wiley, New YorkGoogle Scholar
  15. 15.
    Polat E, Duman U, Duman M, Atici AE, Reyhan E, Dalgic T, Bostanci EB, Yol S (2014) Diagnostic value of preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 in colorectal cancer. Curr Oncol 21(1):e1–e7. doi: 10.3747/co.21.1711 PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Ruol A, Portale G, Castoro C, Merigliano S, Cavallin F, Battaglia G, Michieletto S, Ancona E (2007) Management of esophageal cancer in patients aged over 80 years. Eur J Cardiothorac Surg 32(3):445–448 Epub 2007 Jul 23PubMedCrossRefGoogle Scholar
  17. 17.
    Holscher A, Schroder W, Bollschweiler E, Beckurts K, Schneider P (2003) How safe is high intrathoracic esophagogastrostomy? Chirurg 74:726–733PubMedCrossRefGoogle Scholar
  18. 18.
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics. CA Cancer J Clin. 53(1):5–26PubMedCrossRefGoogle Scholar
  19. 19.
    Derogar M, Sadr-Azodi O, Johar A, Lagergren P, Lagergren J (2013) Hospital and surgeon volume in relation to survival after esophageal cancer surgery in a population-based study. J Clin Oncol 31(5):551–557. doi: 10.1200/JCO.2012.46.1517 PubMedCrossRefGoogle Scholar
  20. 20.
    Pultrum BB, van Westreenen HL, Mulder NH, van Dullemen HM, Plukker JT (2006) Outcome of palliative care regimens in patients with advanced oesophageal cancer detected during explorative surgery. Anticancer Res 26(3B):2289–2293PubMedGoogle Scholar
  21. 21.
    Mortensen MB, Fristrup CW, Ainsworth AP, Pless T, Nielsen HO, Hovendal C (2006) Combined preoperative endoscopic and laparoscopic ultrasonography for prediction of R0 resection in upper gastrointestinal tract cancer. Br J Surg 93(6):720–725PubMedCrossRefGoogle Scholar
  22. 22.
    Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR (2004) Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 58(1):24–38PubMedCrossRefGoogle Scholar
  23. 23.
    Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki K, Watanabe S (1998) CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus 11(1):35–39PubMedGoogle Scholar
  24. 24.
    Mortensen MB, Edwin B, Hünerbein M, Liedman B, Nielsen HO, Hovendal C (2007) Impact of endoscopic ultrasonography (EUS) on surgical decision-making in upper gastrointestinal tract cancer: an international multicenter study. Surg Endosc 21(3):431–438PubMedCrossRefGoogle Scholar
  25. 25.
    Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T (1996) The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am J Gastroenterol 91(1):49–53PubMedGoogle Scholar
  26. 26.
    Kim YC, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Shin JH (2009) Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? J Gastroenterol Hepatol 24(12):1869–1875. doi: 10.1111/j.1440-1746.2009.05935.x PubMedCrossRefGoogle Scholar
  27. 27.
    Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, Yanaga K (2007) Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 14(6):539–544PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2014

Authors and Affiliations

  • Marco Scarpa
    • 1
    Email author
  • Giulia Noaro
    • 1
  • Luca Saadeh
    • 1
  • Francesco Cavallin
    • 1
  • Matteo Cagol
    • 1
  • Rita Alfieri
    • 1
  • Mario Plebani
    • 2
  • Carlo Castoro
    • 1
  1. 1.Surgical Oncology UnitVeneto Institute of Oncology (IOV-IRCCS)PaduaItaly
  2. 2.Department of Laboratory MedicineUniversity of PadovaPaduaItaly

Personalised recommendations